Overview

A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations

Status:
Completed
Trial end date:
2019-04-19
Target enrollment:
Participant gender:
Summary
This is a Phase 1, single-center, open-label randomized, 2×2 crossover (Ref Test | Test Ref) study with a washout of two weeks to establish bioequivalence between single dose of somatrogon in a PEN to somatrogon in VIAL administered sc in healthy male volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Opko Biologics
OPKO Health, Inc.